SCHEDULE: Ayrton Capital Discloses 9.99% Stake in Aptevo
Beneficial Ownership Report
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.
Summary
- Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri collectively reported beneficial ownership of 358,150 shares of Aptevo Therapeutics Inc. common stock.
- This ownership represents 9.99% of Aptevo Therapeutics Inc.'s outstanding common stock.
- The shares are issuable upon the exercise of certain warrants held by the reporting persons.
- The beneficial ownership is subject to a 9.99% blocker, preventing ownership from exceeding this threshold.
- The percentage of class is calculated based on 3,224,156 shares of common stock outstanding as of June 20, 2025, as stated in the Issuer's Prospectus on Form 424B5.
- The holdings of the reporting persons are as of June 30, 2025.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's operational performance or financial health. It simply reports a significant passive investment stake.
Risks
- The shares reported are issuable upon the exercise of warrants, which introduces a dependency on the exercise conditions and potential dilution if exercised.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment in Aptevo Therapeutics, a biotechnology company. Such disclosures are common for investment funds taking positions in public companies, reflecting their investment strategies within the healthcare or biotech sector.
Stakeholder Impact
- Shareholders: Disclosure of a significant passive stake by an investment fund may provide some level of confidence or signal institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 06/20/2025 | Date of Issuer's Prospectus on Form 424B5, used to determine outstanding shares. |
| 06/30/2025 | Date of event which requires filing of this statement; holdings are as of this date. |
| 08/13/2025 | Date of filing of this Schedule 13G statement. |
Keywords
Aptevo Therapeutics, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Beneficial Ownership, Schedule 13G, Warrants, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.